OMERS ADMINISTRATION Corp Sells 88 Shares of Vertex Pharmaceuticals Incorporated $VRTX

by · The Cerbat Gem

OMERS ADMINISTRATION Corp lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 0.6% during the 1st quarter, HoldingsChannel.com reports. The firm owned 13,654 shares of the pharmaceutical company’s stock after selling 88 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Vertex Pharmaceuticals were worth $6,620,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 45 shares during the period. Mascagni Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $31,000. SJS Investment Consulting Inc. raised its position in shares of Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after purchasing an additional 30 shares during the period. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at approximately $46,000. Finally, Stone House Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at approximately $48,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several research reports. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Guggenheim decreased their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a report on Tuesday, August 5th. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Finally, Wolfe Research lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $497.10.

Check Out Our Latest Stock Report on VRTX

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $392.05 on Friday. The company’s fifty day moving average price is $434.34 and its 200-day moving average price is $459.10. The firm has a market capitalization of $100.52 billion, a price-to-earnings ratio of 28.02 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).